Nanoscopic Assessment of Anti-SARS-CoV-2 Spike Neutralizing Antibody Using High-Speed AFM.

SARS-CoV-2 spike nanoparticle SARS-CoV-2 spike protein antibody-dependent enhancement antispike neutralizing antibody high-speed atomic force microscopy nanoimaging receptor-binding domain

Journal

Nano letters
ISSN: 1530-6992
Titre abrégé: Nano Lett
Pays: United States
ID NLM: 101088070

Informations de publication

Date de publication:
25 01 2023
Historique:
pubmed: 16 1 2023
medline: 27 1 2023
entrez: 15 1 2023
Statut: ppublish

Résumé

Anti-spike neutralizing antibodies (S NAbs) have been developed for prevention and treatment against COVID-19. The nanoscopic characterization of the dynamic interaction between spike proteins and S NAbs remains difficult. By using high-speed atomic force microscopy (HS-AFM), we elucidate the molecular property of an S NAb and its interaction with spike proteins. The S NAb appeared as monomers with a Y conformation at low density and formed hexameric oligomers at high density. The dynamic S NAb-spike protein interaction at RBD induces neither RBD opening nor S1 subunit shedding. Furthermore, the interaction was stable at endosomal pH. These findings indicated that the S NAb could have a negligible risk of antibody-dependent enhancement. Dynamic movement of spike proteins on small extracellular vesicles (S sEV) resembled that on SARS-CoV-2. The sensitivity of variant S sEVs to S NAb could be evaluated using HS-AFM. Altogether, we demonstrate a nanoscopic assessment platform for evaluating the binding property of S NAbs.

Identifiants

pubmed: 36641798
doi: 10.1021/acs.nanolett.2c04270
pmc: PMC9881159
doi:

Substances chimiques

Spike Glycoprotein, Coronavirus 0
Antibodies, Viral 0
Antibodies, Neutralizing 0
spike protein, SARS-CoV-2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

619-628

Références

Nature. 2020 Dec;588(7838):498-502
pubmed: 32805734
Biomaterials. 2020 Oct;256:120198
pubmed: 32622019
Cell. 2021 Aug 5;184(16):4203-4219.e32
pubmed: 34242577
Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W665-7
pubmed: 15215472
Science. 2020 Oct 9;370(6513):203-208
pubmed: 32817270
MAbs. 2016 Nov/Dec;8(8):1561-1574
pubmed: 27560842
Nat Immunol. 2021 Dec;22(12):1503-1514
pubmed: 34716452
Nature. 2020 Dec;588(7837):327-330
pubmed: 32942285
PLoS Comput Biol. 2020 Nov 18;16(11):e1008444
pubmed: 33206646
Nat Rev Mol Cell Biol. 2022 Jan;23(1):3-20
pubmed: 34611326
Nat Nanotechnol. 2019 Feb;14(2):184-190
pubmed: 30643273
Nat Commun. 2020 Nov 26;11(1):6013
pubmed: 33243994
Lancet Infect Dis. 2022 Nov;22(11):e311-e326
pubmed: 35803289
Sci Rep. 2021 Jun 4;11(1):11885
pubmed: 34088957
Nano Lett. 2021 Mar 24;21(6):2675-2680
pubmed: 33474931
RSC Adv. 2018 Aug 20;8(51):29378-29384
pubmed: 35547980
Cell Rep. 2022 Mar 1;38(9):110428
pubmed: 35172173
Cells. 2021 Jun 07;10(6):
pubmed: 34200500
Immunity. 2005 May;22(5):539-50
pubmed: 15894272
Nat Rev Immunol. 2019 Sep;19(9):539-549
pubmed: 31019284
N Engl J Med. 2021 Nov 18;385(21):2010-2012
pubmed: 34648703
J Biomed Sci. 2022 Jan 4;29(1):1
pubmed: 34983527
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10037-41
pubmed: 11517324
ACS Nano. 2017 Jun 27;11(6):5567-5578
pubmed: 28530826
Biochim Biophys Acta Gen Subj. 2020 Feb;1864(2):129313
pubmed: 30825615
Cell. 2021 Jun 24;184(13):3452-3466.e18
pubmed: 34139176
Nat Commun. 2014 Jul 10;5:4394
pubmed: 25008037
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Mol Cell. 2016 Jul 7;63(1):135-45
pubmed: 27320199
J Extracell Vesicles. 2021 Dec;10(14):e12170
pubmed: 34874124
Nano Lett. 2020 Sep 9;20(9):6320-6328
pubmed: 32787163
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
J Pharm Sci. 2022 Jun;111(6):1587-1598
pubmed: 35235843
Science. 2021 Dec 24;374(6575):1626-1632
pubmed: 34735219
Cell. 2021 Jun 10;184(12):3192-3204.e16
pubmed: 33974910
Cell Host Microbe. 2020 Dec 9;28(6):867-879.e5
pubmed: 33271067
J Phys Chem Lett. 2021 Apr 22;12(15):3837-3846
pubmed: 33852305
Cell Host Microbe. 2021 May 12;29(5):744-746
pubmed: 33984277
ACS Cent Sci. 2017 Aug 23;3(8):839-846
pubmed: 28852697
Nano Lett. 2019 Jul 10;19(7):4787-4796
pubmed: 31184907
Sci Transl Med. 2022 Mar 23;14(637):eabn8057
pubmed: 35166573

Auteurs

Keesiang Lim (K)

WPI-Nano Life Science Institute, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan.

Goro Nishide (G)

Division of Nano Life Science in the Graduate School of Frontier Science Initiative, WISE Program for Nano-Precision Medicine, Science and Technology, Kanazawa University, Kanazawa, Ishikawa 920-1192, Japan.

Elma Sakinatus Sajidah (ES)

Division of Nano Life Science in the Graduate School of Frontier Science Initiative, Kanazawa University, Kanazawa Ishikawa 920-1192, Japan.

Tomoyoshi Yamano (T)

WPI-Nano Life Science Institute, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan.
Department of Immunology, Kanazawa University Graduate School of Medical Sciences, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8640, Japan.

Yujia Qiu (Y)

Division of Nano Life Science in the Graduate School of Frontier Science Initiative, Kanazawa University, Kanazawa Ishikawa 920-1192, Japan.

Takeshi Yoshida (T)

Department of Immunology, Kanazawa University Graduate School of Medical Sciences, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8640, Japan.

Akiko Kobayashi (A)

Cell-Bionomics Research Unit, Institute for Frontier Science Initiative (INFINITI), Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan.

Masaharu Hazawa (M)

WPI-Nano Life Science Institute, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan.
Cell-Bionomics Research Unit, Institute for Frontier Science Initiative (INFINITI), Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan.

Toshio Ando (T)

WPI-Nano Life Science Institute, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan.

Rikinari Hanayama (R)

WPI-Nano Life Science Institute, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan.
Department of Immunology, Kanazawa University Graduate School of Medical Sciences, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8640, Japan.

Richard W Wong (RW)

WPI-Nano Life Science Institute, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan.
Cell-Bionomics Research Unit, Institute for Frontier Science Initiative (INFINITI), Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH